×
Revance Therapeutics EBIT 2012-2024 | RVNC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Revance Therapeutics ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Revance Therapeutics EBIT 2012-2024 | RVNC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Revance Therapeutics ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$160.1B
Vertex Pharmaceuticals (VRTX)
$123.9B
Gilead Sciences (GILD)
$122.2B
Bristol Myers Squibb (BMY)
$116.5B
CSL (CSLLY)
$82.8B
Regeneron Pharmaceuticals (REGN)
$79.3B
GSK (GSK)
$75.4B
Argenex SE (ARGX)
$40B
Alnylam Pharmaceuticals (ALNY)
$35.9B
BioNTech SE (BNTX)
$28.8B
BeiGene (ONC)
$22.4B
Biogen (BIIB)
$20.7B
Illumina (ILMN)
$19.5B
Insmed (INSM)
$14.5B
Incyte (INCY)
$14.4B
Intra-Cellular Therapies (ITCI)
$13.5B
Moderna (MRNA)
$12.9B
Genmab (GMAB)
$12.8B
Genmab (GNMSF)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.3B
Bio-Techne Corp (TECH)
$11.9B
Vaxcyte (PCVX)
$11.1B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.7B
Exact Sciences (EXAS)
$10B
Bio-Rad Laboratories (BIO.B)
$9.6B
Exelixis (EXEL)
$9.6B
QIAGEN (QGEN)
$9.4B
Repligen (RGEN)
$9.1B
Roivant Sciences (ROIV)
$7.9B